EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report

Roudy Issa iD, Bassem Akiki iD, Sophie Georgin-Lavialle iD, Olivier Kosmider iD, Danielle Hammond iD, Marcel Massoud iD, Vicky Najjar, Elissar Dagher iD

Case Reports in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/crh/3903470 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Hematology, online erschienen am 13.05.2026. Verfasst von Roudy Issa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Immunology, Notre Dame des Secours University Hospital, Jbeil, Lebanon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic (VEXAS) syndrome is a rare, adult‐onset autoinflammatory disease that has only been described since late 2020. Given the rarity of the disease and the absence of established treatment guidelines, management remains challenging and largely based on clinical experience and case reports. Case presentation This paper reports the first documented case of VEXAS syndrome in Lebanon. A 73‐year‐old man presented with fever, severe asthenia, erythematous skin lesions, and anemia, initially diagnosed as giant cell arteritis. Following a diagnosis of VEXAS syndrome, he was treated with corticosteroids and methotrexate but developed refractory anemia and required erythropoietin therapy. Tocilizumab was introduced to manage inflammation, but the patient’s condition remained challenging due to corticosteroid dependence and myelodysplastic syndrome (MDS). Given the patient’s comorbidities and intermediate‐risk MDS, azacitidine was initiated as a therapeutic option. Despite initial neutropenia and infections, adjustments to the azacitidine regimen led to significant clinical and hematologic improvements. The patient achieved complete remission, became transfusion‐independent, and maintained stable hemoglobin levels.

Conclusion

This case highlights the efficacy of azacitidine in managing VEXAS syndrome with MDS, particularly among patients ineligible for hematopoietic stem cell transplantation, offering a potential pathway to sustained remission and reduced corticosteroid dependence.

Schlagwörter

Stichwörter der Autor:innen

VEXAS syndromeazacitidinecase reportmyelodysplastic syndrome

Autor:innen und Institutionen

  • Department of Internal Medicine and Clinical Immunology, Notre Dame des Secours University Hospital, Jbeil, Lebanon.
  • Department of Gastroenterology and Hepatology, Notre Dame des Secours University Hospital, Jbeil, Lebanon.
  • Department of Internal Medicine, Sorbonne University, AP-HP Tenon, Paris, France, sorbonne-universites.fr.
  • Department of Biological Hematology, Paris Cite University, AP-HP Cochin, Paris, France.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
  • Department of Hematology/Oncology, Notre Dame des Secours University Hospital, Jbeil, Lebanon.

ORCID-Profile: Roudy Issa, Bassem Akiki, Sophie Georgin-Lavialle, Olivier Kosmider, Danielle Hammond, Marcel Massoud, Elissar Dagher

Zitieren

APA

Issa, R., Akiki, B., Georgin-Lavialle, S., Kosmider, O., Hammond, D., Massoud, M., Najjar, V., & Dagher, E. (2026). The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/3903470

Vancouver

Issa R, Akiki B, Georgin-Lavialle S, Kosmider O, Hammond D, Massoud M, et al. The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/3903470

BibTeX
@article{Issa2026,
  author = {Issa, Roudy and Akiki, Bassem and Georgin-Lavialle, Sophie and Kosmider, Olivier and Hammond, Danielle and Massoud, Marcel and Najjar, Vicky and Dagher, Elissar},
  title = {The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report},
  journal = {Case Reports in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crh/3903470}
}
Kostenlos starten →